Table 2. Therapy for visceral leishmaniasis in HIV-coinfected patients in the Mediterranean area.

Treatment	Grade for VL/HIV in the Mediterranean Basin Caused by L. infantum
Amphotericin B deoxycholate 20 mg/kg as 0.7 mg/kg/day IV for 28 days.	BI
Amphotericin B lipid complex total dose 30 mg/kg as 3 mg/kg/day IV for 10 days	BI
Liposomal amphotericin B total dose of 50 (40–60) mg/kg as 4 mg/kg/day IV on days 1–5, 10, 17, 14, 31, and 38	BIII
Meglumine antimoniate (IM or IV): 20 mg Sbv+/kg/d (without upper limit of 850 mg/d) for 28 d	CI
Miltefosine: 100–150 mg/day po for 28 days	CIII
Combination therapy: Liposomal amphotericin B+paromomycin or miltefosine	No data

Evidence-based recommendation. Strength of recommendation: A = Good evidence to support a recommendation for use; B = Moderate evidence to support a recommendation for use; C = Poor evidence to support a recommendation; D = Moderate evidence to support a recommendation against use; E = Good evidence to support a recommendation against use.

Quality of evidence: I = Evidence from one or more randomized clinical trials; II = Evidence from one or more well-designed clinical trials, without randomization; from cohort or case-controlled analytic studies (preferably from >1 center); from multiple time series; or from dramatic results from uncontrolled experiments; III = Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees [77], [78]. Abbreviations: IM, intramuscular; IV, intravenous; po, per os.